Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Jetstar to Charge for Overhead Cabin Bags From February 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Apple Restores Telegram to App Store After Content Policy Violation 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Company Announcement - No. 10/2018
Zealand Pharma convenes its Annual General Meeting 2018
| Copenhagen, March 22, 2018 - Zealand Pharma A/S ("Zealand") convenes the Company's ordinary Annual General Meeting to be held on |
| Thursday April 19, 2018 at 3.00 pm CET |
| at the offices of Plesner Advokatpartnerselskab, Amerika Plads 37, 2100 Copenhagen Ø, Denmark. |
| Agenda: |
| Management's report on the Company's activities during the past financial year |
| Approval of the audited Annual Report 2017 |
| Resolution on the distribution of profit or the cover of loss in accordance with the approved Annual Report 2017 |
| Election of members to the Board of Directors |
| Election of the auditor |
| Authorization for the Company to acquire treasury shares directly and/or acquire American depositary shares |
| Proposal from the Board of Directors to update the Company's Remuneration Policy and the Overall Guidelines for Incentive pay to the Executive Management of Zealand Pharma A/S |
| Proposal by the Board of Directors to approve the fees for the Board of Directors for the financial year 2018 |
| Proposal by the Board of Directors to dissolve the Shareholder Nomination Committee, including proposal to delete Section 15 of the Company's Articles of Association |
| Proposal by the Board of Directors to amend the Company's Articles of Association, including (i) amendment of Section 5.8 to reflect the CVR no. of Computershare A/S, (ii) deletion of expired paragraphs in Section 8.1, (iii) update of the name of the Danish Business Authority in Section 9.2 and 9.8, (iv) amendment of Section 9.16 to ensure consistency between the Danish and English version of this Section and (v) deletion of the used authorization on electronic communication in Section 12.5 and (vi) deletion of Section 13.3 regarding retirement age for members of the Board of Directors |
| Proposal from the Board of Directors to approve a new authorisation to increase the capital of the Company |
| Any other business |
| The Annual General Meeting will be held in English. After the Annual General Meeting 2018, refreshments (coffee and cake) will be served, and there will be an opportunity to speak with members of Zealand's Corporate Management team. The notice to convene the Annual General Meeting as well as the registration and proxy forms are available on Zealand's website via the following link: www.zealandpharma.com/annual-general-meeting/ The notice to convene is enclosed to this announcement, and the following should be noted: |
| Agenda item no. 4: The board members elected by the General Meeting are elected on an annual basis. All of the incumbent board members are standing for re-election, and the Nomination Committee proposes the re-election of all the members: Rosemary Crane Catherine Moukheibir Alain Munoz Martin Nicklasson Michael J. Owen In addition the Nomination Committee proposes the election of an additional independent member of the Board of Directors: Kirsten Aarup Drejer For a description of the nominated candidates, see Appendix 1 to this notice. |
For further information, please contact:
Britt Meelby Jensen, President and CEO
Tel.: +45 51 67 61 28, e-mail: [email protected]
Mats Blom, Executive Vice President and Chief Financial Officer
Tel.: +45 31 53 79 73, e-mail: [email protected]
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of proprietary medicines in late-stage clinical development focused on specialty gastrointestinal and metabolic diseases. In addition, Zealand has two marketed drugs under license to Sanofi and two compounds in clinical development under license to Boehringer Ingelheim.
Attachment:
http://www.globenewswire.com/NewsRoom/AttachmentNg/f14f2e1c-1541-4783-8f3c-8943dd6759ce
